tiprankstipranks
Burcon Nutrascience (TSE:BU)
TSX:BU
Canadian Market
Want to see TSE:BU full AI Analyst Report?

Burcon Nutrascience (BU) Earnings Dates, Call Summary & Reports

76 Followers

Earnings Data

Report Date
Aug 17, 2026
TBA (Confirmed)
Period Ending
2027 (Q1)
Consensus EPS Forecast
-0.07
Last Year’s EPS
-0.27
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2026
Earnings Call Date:Jun 24, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call emphasized strong operational progress and accelerating commercial traction — material revenue growth (nearly sixfold YoY), expanding customer pipeline (200+ projects and 30+ active buyers), repeat orders, and significant production improvements (60% higher daily production). Management also demonstrated cost discipline (G&A -23%, R&D -65%) and secured partial financing with partner and insider support. Primary challenges are the small absolute revenue base ($2.3M), remaining facility capital work and capacity planning, lengthy customer adoption cycles (9–18 months), and ongoing liquidity/financing considerations. Overall, the positive operational momentum and validated customer demand outweigh the early-stage risks and financing needs, but execution against scaling and profitability targets remains critical.
Company Guidance
Management guided to achieve $10 million in sales in calendar 2026 and reach positive operating cash flow, forecasting significant quarter‑over‑quarter revenue growth into fiscal 2027 with fiscal Q1 expected to grow about 50% versus the prior quarter. They pointed to FY2026 operational results of $2.3 million revenue (nearly sixfold year‑over‑year), double‑digit QoQ growth in Q3 and Q4, a 60% higher daily production record versus the previous quarter, more than 200 active projects, 30+ active buyers, and three new product launches, alongside cost discipline (G&A down 23% and R&D down 65%). They also noted a $6.9 million convertible note financing (with $4.0 million closed in FY26), that the ProMan‑funded remaining capex will give the facility the capability to meet committed demand, and cited an 8–10% long‑term protein market CAGR.
Revenue Growth
Fiscal 2026 revenues of $2.3 million, a nearly sixfold year-over-year increase (≈+400–500%), demonstrating a clear translation of operational progress into sales.
Quarter-over-Quarter Momentum
Double-digit quarter-over-quarter revenue growth in both Q3 and Q4 of fiscal 2026, with management indicating fiscal Q1 (subsequent quarter) is expected to deliver ~50% quarter-over-quarter growth.
Expanding Customer Base and Pipeline
More than 200 active customer projects in the pipeline and 30+ active buyers across the product portfolio, showing breadth and diversification across food applications, brand types and products.
Product Commercialization and Repeat Orders
Commercial production launched for multiple plant-protein products (pea, canola, and FiberPro), with repeat customer orders across the portfolio — a key validation of product quality and adoption.
Production Scaling and Record Performance
Commissioned technology at commercial scale with production improvements; achieved a production performance record of daily production 60% higher than the previous quarter, supporting the ability to meet growing demand.
Quality and Third-Party Validation
Facility audited and certified (BRC) and allergen-free status highlighted — strengthening commercial credibility and reducing customer adoption friction.
Cost Discipline
Management prioritized commercial operations leading to year-over-year reductions in operating expenses: general & administrative down 23% and research & development down 65% in fiscal 2026.
Financing Progress and Partner Support
Announced $6.9 million private placement of convertible notes; $4.0 million closed in fiscal 2026 with the balance closed subsequent to year end. Notable participation by insiders and facility owners underscores partner confidence.
Clear Growth Targets
Management set explicit targets: $10 million in sales in calendar 2026 and achieving positive operating cash flow, providing investors with a concrete near-term objective.

Burcon Nutrascience (TSE:BU) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

TSE:BU Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 17, 2026
2027 (Q1)
-0.07 / -
-0.27
Jun 24, 2026
2026 (Q4)
-0.10 / -0.30
-0.3411.76% (+0.04)
Feb 11, 2026
2026 (Q3)
0.00 / -0.28
-0.2-40.00% (-0.08)
Nov 12, 2025
2026 (Q2)
-0.05 / -0.28
-0.33115.41% (+0.05)
Aug 13, 2025
2026 (Q1)
-0.07 / -0.27
-0.165-63.64% (-0.11)
Jun 25, 2025
2025 (Q4)
0.00 / -0.34
-0.165-106.06% (-0.18)
Feb 14, 2025
2025 (Q3)
-0.17 / -0.20
-0.33139.58% (+0.13)
Nov 14, 2024
2025 (Q2)
-0.17 / -0.33
-0.165-100.61% (-0.17)
Aug 14, 2024
2025 (Q1)
- / -0.17
-0.33150.15% (+0.17)
Jun 26, 2024
2024 (Q4)
- / -0.17
-0.1650.00% (0.00)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

TSE:BU Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Jun 24, 2026
C$2.29C$1.91-16.59%
Feb 11, 2026
C$1.88C$1.91+1.60%
Nov 12, 2025
C$2.29C$2.00-12.66%
Aug 13, 2025
C$2.73C$2.730.00%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Burcon Nutrascience (TSE:BU) report earnings?
Burcon Nutrascience (TSE:BU) is schdueled to report earning on Aug 17, 2026, TBA (Confirmed).
    What is Burcon Nutrascience (TSE:BU) earnings time?
    Burcon Nutrascience (TSE:BU) earnings time is at Aug 17, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is TSE:BU EPS forecast?
          TSE:BU EPS forecast for the fiscal quarter 2027 (Q1) is -0.07.